Scientists find first new antibiotic for gonorrhoea since the 1990s amid rise in ‘super' strains
Scientists have found the first new antibiotic treatment for gonorrhoea since the 1990s amid fears over the rise of 'untreatable' strains of the sexually transmitted infection.
Gepotidacin, an antibiotic currently used to treat urinary tract infections, can also treat gonorrhoea, experts have found.
It comes after researchers in antibiotic-resistant infections.
The research, published in the Lancet on Monday, compared the treatment of 622 patients for gonorrhoea with the current standard injected antibiotic, called ceftriaxone, with a new treatment using an oral antibiotic pill called gepotidacin.
They found the pill to be as effective as the current standard treatment and also found it worked against the strains of the STI, N gonorrhoeae, that are resistant to existing antibiotics.
An editorial published in the Lancet alongside the study warned that global targets to reduce the number of new cases of gonorrhoea among people aged 15–49 years old from 82.3 million per year in 2020 to 8.23 million per year in 2030, might not be achieved due to the resistant strains.
It added: 'There is the risk that soon gonorrhoea will be impossible to treat in the absence of new drugs or strategies to curb the burden of disease… What we are seeing with N gonorrhoeae is a challenge that could extend easily to other bacteria with worsening of the antimicrobial resistance landscape.'
The study was carried out by researchers from Birmingham University Hospitals, Leeds Teaching Hospitals NHS Trust, Emory University, Louisiana State University Health Sciences Center, Sydney Medical School, and pharmaceutical company, GlaxoSmithKline (GSK) which manufactures gepotidacin.
Authors note that resistant trains are prevalent in several Asian countries, and have been increasingly confirmed across Europe.
Last month the UK Health Security Agency published an alert over the rise in antibiotic-resistant gonorrhoea cases and 'extensively' drug-resistant strains.
Since 2015 there have been 42 cases of ceftriaxone-resistant gonorrhoea and fifteen of those were extensively resistant meaning they were also resistant to second option treatments.
From January 2024 to March 2025, nine cases of the super-resistant strain were recorded, compared to five cases in two years prior.
Cases of antibiotic-resistant gonorrhoea come after a record 85,000 cases were reported in England in 2023, and a rise in STI diagnosis more broadly in the UK.
Researchers said: 'Cases of drug-resistant gonorrhoea have increased rapidly in recent years, reducing the options for treatment. There is an urgent need for new treatments for gonorrhoea with no new antibiotics since the 1990s.'
'The new treatment could be an important tool in combating the rise of gonorrhoea strains that are becoming resistant to the standard treatment. Additionally, treatment as a pill alone without the need for an injection would likely improve patient experiences and reduce healthcare resources.'
However, researchers advised the study results must be treated with caution as the majority of the participants, 74 per cent, were white men and so said more research would be needed for the impact in women, adolescents and other ethnicities.
In a comment piece authors, also warned that strains resistant to the new treatment, gepotidacin, will develop and said the development of additional treatments remains important.
They said: 'In conclusion, gepotidacin is promising for the treatment of gonorrhoea, but the challenges to retain gonorrhoea as a treatable infection will continue. As emphasised by WHO, five key priorities crucial for effective management and control of gonorrhoea include improved prevention.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
2 days ago
- BBC News
Gonorrhoea vaccinations to start in Northern Ireland in August
The Department of Health has said a targeted vaccination programme against gonorrhoea has been approved across Northern Ireland. Eligible patients will be offered the vaccine from August 2025, the department said. Those eligible include gay and bisexual men who have a recent history of multiple sexual partners or have recently had a sexually transmitted infection (STI). Gonorrhoea is now the most prevalent STI diagnosed in sexual health clinics in Northern Ireland, according to the Public Health Agency (PHA). England will also begin its vaccination roll out in August this vaccine roll out will also focus mainly on gay and bisexual men with a history of multiple sexual partners or an was given by the Joint Committee on Vaccination and Immunisation (JCVI) in November 2023, which recommended roll out of the vaccine following an upsurge in gonorrhoea Minister Mike Nesbitt said the launch of the vaccine programme is "important and very timely for Northern Ireland's public health". He added that by targeting those "most at risk", there is an "opportunity to curb the spread and reduce transmission rates". The vaccine is an existing one for meningococcal B disease, called 4CMenB. The UK Health Security Agency (UKHSA) research shows that those who receive the jab could be protected from the STI by up to 40% and it could help tackle levels of antibiotic-resistant strains of the disease. Record number of gonorrhoea cases PHA figures for Northern Ireland show that between 2021 and 2022 the number of cases jumped from 652 to 1,606 - the highest number recorded by the were 951 cases in 2019, but that dropped to 455 in 2020, likely due to changes in behaviour and healthcare associated with the Covid 2023, there were 1,561 new cases, accounting for almost a third (28%) of all new STI diagnoses in Northern Ireland. Of those diagnosed, 75% were males and of those 67% were gay, bisexual and men who have sex with does not always have symptoms, but they can include pain, unusual discharge, inflammation of the genitals and infertility. The chief medical officer said the vaccine roll-out will have "significant public health benefits for both those who receive the vaccine, and the wider population".Sir Michael McBride said the programme has "the potential to result in less patients presenting with more complex cases and clusters of gonorrhoea".He encouraged all those eligible to take up the vaccine when offered. What is gonorrhoea? Gonorrhoea is easily passed from person to person through unprotected one in 10 infected men and almost half of infected women do not experience any infection can be passed from a pregnant woman to her baby, and without treatment, can cause permanent blindness for a newborn is not spread by non-sexual contact like is not transmitted through surfaces and materials like toilet seats, towels, cups or you have had successful treatment for gonorrhoea before, you can still catch it NHS.
The Guardian
3 days ago
- The Guardian
Millions in west do not know they have aggressive fatty liver disease, study says
More than 15 million people in the US, UK, Germany and France do not know they have the most aggressive form of fatty liver disease, according to research. Metabolic dysfunction-associated steatotic liver disease (MASLD) – the formal name for non-alcoholic fatty liver disease – occurs in people who drink no or minimal amounts of alcohol whose liver contains more than 5% fat. Around two-thirds of patients with type 2 diabetes are thought to have the condition, which is also associated with obesity, heart and circulatory disease. Around 5% of adults globally have the most aggressive form of MASLD. Metabolic dysfunction-associated steatohepatitis (MASH) causes fibrosis (scarring) and can lead to cirrhosis and is linked to greater risk of cardiovascular disease, chronic kidney disease and liver cancer. But the vast majority of people do not know they have the condition. An international group of researchers examined prevalence and diagnosis of aggressive fatty liver disease in the US, UK, Germany and France. The researchers found that just under 3% of people in the UK, France and Germany, and 4% of those in the US have MASH, but diagnosis rates were below 18%. That means about 20 million people in the US, UK, Germany and France are living with MASH but only 2.5 million people have a diagnosis, leaving more than three-quarters – about 16.7 million people – unaware they have the condition. The report, published in the Lancet Regional Health Europe and presented at an the meeting of the global thinktank on steatotic liver disease in Barcelona, Spain on Thursday, calls for a doubling in diagnosis rates from 2022 levels. Traditionally, MASH was diagnosed through biopsy, but now non-invasive methods, such as blood tests, ultrasound and MRI scans can be used. As a result, everyone with type 2 diabetes; obesity combined with one or more other risk factors; and those with persistently high liver enzymes should be screened for MASH, the researchers conclude. Dr Jeffrey Lazarus, the lead author of the paper and a professor of global health in New York and Barcelona, said: 'Undiagnosed MASH costs economies billions of pounds in lost productivity and poor health. Unless diagnosis rates are doubled, alongside similar increases in treatment and care, direct health costs alone are predicted to triple over the next 20 years.' Responding to the findings, Emmanouil Tsochatzis, a professor of hepatology at UCL and a consultant hepatologist at the Royal Free hospital, said: 'More than 15 million people across the US and Europe have the deadliest form of fatty liver disease – and don't know it. Without faster diagnosis and access to treatment, the human and economic toll will skyrocket.' The research has also prompted renewed calls for weight loss jabs to be used to treat MASH. Dr Paul Brennan, a co-author of the Lancet paper and a hepatologist at NHS Tayside, said: 'GLP-1s (including Wegovy and Mounjaro) offer the potential to resynchronise our metabolism, by introducing feelings of satiety – fullness – and delaying the time the stomach takes to empty. These effects often result in reduced calorie intake, and improvements in how the liver handles nutrients as a result of weight loss, thus reducing scar tissue formation in the liver.' Michael Betel, the president of the Fatty Liver Alliance, said: 'Too many people living with type 2 diabetes or obesity are never tested for MASH until it's too late. We need a huge increase in liver health assessments in patients living with these diseases, alongside lifestyle changes and for some, when appropriate, weight loss drugs to reduce blood sugar and appetite. While weight loss drugs weren't created to treat liver disease, trials suggest they could benefit multiple metabolic-related conditions, and improve our liver health.' Separately a study published on Wednesday found that the diabetes drug dapagliflozin, which reduces blood sugar levels, can also reduce fat levels and fibrosis in the liver.
STV News
3 days ago
- STV News
Exhibition of prehistoric Giants to make UK debut
An exhibition of giant prehistoric animals will make its UK debut this year. Giants, developed by the Royal Belgian Institute of Natural Sciences and toured by Nomad Exhibitions, will open at Birmingham Museum and Art Gallery on August 2. It will then move to the National Museum of Scotland in Edinburgh in January 2026. The exhibition focuses on creatures such as the woolly mammoth, which roamed the Earth after the extinction of the dinosaurs. Giants spans a period of 66 million years to the present day, and highlights the need to protect existing giant species such as elephants and whales. It features life-sized 3D models and nearly complete skeletons, including giant shark Otodus megalodon; the Mammuthus primigenius or woolly mammoth, which weighed between six and eight tonnes; and Gigantopithecus blacki, an Asian primate the size of three orangutans. Visitors of all ages are encouraged to step into the shoes of palaeontologists and biologists, using interactive resources and engaging with the scientific processes behind fossil discovery and reconstruction. PA Media A life-sized 3D model of a megalodon features in the exhibition (National Museums Scotland/PA). Immersive projections recreate the natural habitats of previous giant species, providing context to their existence and extinction. The exhibition also warns of the threat of extinction posed to elephants, rhinoceroses and whales and the 'urgent need' to protect endangered species. The announcement coincides with World Environment Day on Thursday, which this year is focused on ending plastic pollution. Zak Mensah and Sara Wajid, co-chief executives of Birmingham Museums Trust, said: 'We are delighted to welcome the Giants exhibition to Birmingham Museum and Art Gallery. 'This inspiring installation not only captures the imagination with its monumental scale but also delivers a vital message about sustainability and our shared responsibility to protect the planet. 'Birmingham Museums is committed to using storytelling to engage communities with the challenges of our time and Giants does exactly that in a powerful and accessible way.' Dr Nick Fraser, keeper of Natural Sciences at National Museums Scotland, said: 'We're really looking forward to bringing Giants to Scotland next year. 'Popular attention on prehistoric life tends to focus either on dinosaurs or on our own earliest human ancestors, which leaves a relatively neglected gap of around 60 million years of natural history. 'Giants is a striking invitation to us all to think about that period, to see how nature adapts over time, and also to reflect on the ways in which current human activity is denying that time to today's endangered giants.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
